氧化壓力測定市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

2023 年，全球氧化壓力檢測市場價值為 11 億美元，預計 2024 年至 2032氧化壓力複合年成長率為 9.8%。的實驗室測試。透過評估活性氧 (ROS) 和抗氧化劑之間的平衡，它們為氧化壓力引起的細胞和組織損傷提供了寶貴的見解。

市場分為兩大類：儀器和消耗品。在消耗品領域，檢測試劑盒和試劑預計將顯著成長，預計到2032 年該領域將達到15 億美元。一致性結果，使不同專業水平的實驗室都可以輕鬆獲得它們。這種易用性和可靠性正在推動整個市場的更廣泛採用。

根據檢測類型，2023 年間接檢測領域的市場價值為 4.661 億美元。其簡單的程序有助於最大限度地減少錯誤並加快測試過程，使其成為研究和臨床實驗室常規使用的理想選擇。

到 2032 年，美國氧化壓力檢測產業預計將成長至 9.217 億美元。此外，美國市場受益於強大的監管環境，並受到食品藥物管理局 (FDA) 等機構的監督。該法規確保氧化壓力測定符合嚴格的安全性和準確性標準，增強消費者的信任並鼓勵市場進一步成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 慢性病盛行率增加
    • 診斷技術的進步
    • 提高抗氧化療法的認知
    • 藥物發現和開發研究不斷增加
  • 產業陷阱與挑戰
    • 儀器成本高
    • 嚴格的監管挑戰
• 成長潛力分析
• 監管環境
• 技術景觀
  • 核心技術
  • 鄰近技術
• 未來市場趨勢
• 差距分析
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品分類，2021 - 2032 年

• 主要趨勢
• 儀器儀表
• 耗材
  • 套件
  • 試劑

第 6 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 間接測定
  • 基於蛋白質的檢測
  • 基於脂質的測定
  • 基於核酸的檢測
• 抗氧化能力測定
  • 穀胱甘肽測定
  • 抗壞血酸測定
  • 基於細胞的外源性抗氧化劑測定
• 基於酵素的測定
• 基於活性氧的測定

第 7 章：市場估計與預測：按技術分類，2021 - 2032

• 主要趨勢
• 酵素連結免疫吸附測定法 (ELISA)
• 流式細胞儀
• 色譜法
• 顯微鏡檢查
• 其他技術

第 8 章：市場估計與預測：按疾病類型，2021 - 2032

• 主要趨勢
• 心血管疾病
• 呼吸系統疾病
• 癌症
• 糖尿病
• 其他疾病

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 製藥和生物技術產業
• 學術研究機構
• 合約研究組織 (CRO)
• 臨床實驗室
• 其他最終用戶

第 10 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：公司簡介

• AMSBIO
• ABCAM
• Agilent Technologies
• Biorbyt
• Cayman Chemical
• Cell Biolabs
• Dojindo Molecular Technologies
• Enzo Biochem
• GenScript Biotech Corporation
• LifeSpan BioSciences
• Merck
• Promega Corporation
• QIAGEN
• RayBiotech
• Thermo Fisher Scientific

The Global Oxidative Stress Assay Market was valued at USD 1.1 billion in 2023 and is projected to grow at 9.8% CAGR from 2024 to 2032. These assays are laboratory tests utilized to evaluate oxidative stress biomarkers in samples like blood, urine, or tissue. By assessing the balance between reactive oxygen species (ROS) and antioxidants, they offer valuable insights into cellular and tissue damage caused by oxidative stress.

The market is segmented into two main categories: instruments and consumables. Within the consumables segment, assay kits and reagents are expected to see significant growth, with the segment projected to reach USD 1.5 billion by 2032. Pre-packaged consumables, such as ready-to-use kits and reagents, simplify assay workflows and ensure consistency in results, making them highly accessible for laboratories across various expertise levels. This ease of use and reliability is driving broader adoption across the market.

Based on assay type, the market from the indirect assays segment was valued at USD 466.1 million in 2023. These assays are favored for their simplicity and user-friendliness, making them an attractive option for both researchers and clinicians. Their straightforward procedures help minimize errors and speed up the testing process, making them ideal for routine use in research and clinical laboratories.

The U.S. oxidative stress assay industry is expected to grow to USD 921.7 million by 2032. The increasing prevalence of chronic conditions, such as cardiovascular diseases, diabetes, and cancer, is driving the demand for effective diagnostic and therapeutic solutions. Additionally, the U.S. market benefits from a strong regulatory environment, with oversight from agencies such as the Food and Drug Administration (FDA). This regulation ensures that oxidative stress assays meet stringent safety and accuracy standards, boosting consumer trust and encouraging further market growth.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Advances in diagnostic technologies
    • 3.2.1.3 Increasing awareness of antioxidant therapies
    • 3.2.1.4 Rising research in drug discovery and development
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of instruments
    • 3.2.2.2 Stringent regulatory challenges
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Gap analysis
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Instruments
• 5.3 Consumables
  • 5.3.1 Kits
  • 5.3.2 Reagents

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Indirect assays
  • 6.2.1 Protein-based assays
  • 6.2.2 Lipid-based assays
  • 6.2.3 Nucleic acid-based assays
• 6.3 Antioxidant capacity assays
  • 6.3.1 Glutathione assays
  • 6.3.2 Ascorbic acid assays
  • 6.3.3 Cell-based exogenous antioxidant assays
• 6.4 Enzyme-based assays
• 6.5 Reactive oxygen species-based assays

Chapter 7 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Enzyme-Linked Immunosorbent Assay (ELISA)
• 7.3 Flow cytometry
• 7.4 Chromatography
• 7.5 Microscopy
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Cardiovascular disease
• 8.3 Respiratory diseases
• 8.4 Cancer
• 8.5 Diabetes
• 8.6 Other diseases

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Pharmaceutical and biotechnology industries
• 9.3 Academic research institutes
• 9.4 Contract Research Organizations (CROs)
• 9.5 Clinical laboratories
• 9.6 Other end users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 AMSBIO
• 11.2 ABCAM
• 11.3 Agilent Technologies
• 11.4 Biorbyt
• 11.5 Cayman Chemical
• 11.6 Cell Biolabs
• 11.7 Dojindo Molecular Technologies
• 11.8 Enzo Biochem
• 11.9 GenScript Biotech Corporation
• 11.10 LifeSpan BioSciences
• 11.11 Merck
• 11.12 Promega Corporation
• 11.13 QIAGEN
• 11.14 RayBiotech
• 11.15 Thermo Fisher Scientific